Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases

Table 1 Main characteristics of patients according to treatment group before and after matching or weighting

Median [Q1-Q3]	Allo-SCT	Controls	p-value
N (%)
MM
Original set	n=23	n=142
Age	48 [40.5-51]	51.5 [47–55]	0.005
Beta2 ≥ 3.5	4 (17 %)	52 (37 %)	0.12
Months to relapse	16 [11–32.5]	26.5 [17–38]	0.014
Matched set	n=21	n=21
Age	49 [41–51]	46 [42–50]	0.24
Beta2 ≥ 3.5	4 (19 %)	4 (19 %)	0.71
Months to relapse	17 [13–33]	24 [17–32]	0.22
Weighted set	n=268	n=165
Age	56 [51–58]	51 [46–54]	0.15
Beta2 ≥ 3.5	4 (19%)	4 (19%)	0.28
Months to relapse	58 [26–70]	25 [17–36]	0.08
FL
Original set	n=28	n=115
Age	38 [33–42]	46 [40–52]	0.0001
No previous regimens	4 [3, 4]	3 [2–4]	0.005
Months to relapse	6.7 [5.6-9.2]	4.6 [3.7-6.1]	0.0001
Matched set	n=19	n=19
Age	38 [33–42]	38 [33–45]	0.35
No previous regimens	3 [3, 4]	3 [3, 4]	0.90
Months to relapse	6.3 [4.7-8.9]	7.8 [4.0-10.7]	0.82
Weighted set	n=78	n=117
Age	39 [35–46]	44 [34–50]	0.42
No previous regimens	3 [3, 4]	3 [2–4]	0.16
Months to relapse	5.9 [4.7-7.4]	5.3 [3.8-9.3]	0.03
Hodgkin disease
Original set	n=23	n=19
Age	23 [19–29]	29 [24–35]	0.05
No previous regimens	4 [3, 4]	4 [4, 5]	0.05
Months to relapse	1.2 [0–9.2]	2.4 [0–7.2]	0.94
Matched set	n=15	n=15
Age	24 [21–31]	25 [23–30]	0.98
No previous regimens	3 [3, 4]	4 [4, 5]	0.21
Months to relapse	1.9 [0.3-9.9]	1.8 [0–5.4]	0.49
Weighted set	n=41	n=40
Age	26 [20–49]	25 [20–32]	0.71
No previous regimens	3 [3, 4]	4 [4]	0.17
Months to relapse	0.1 [0–0.7]	0.1 [0–0.5]	0.35

ISSN: 2052-1839